Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

-- Quarter Highlighted by Cinryze(TM) [C1 Inhibitor (human)] Commercial Launch --

EXTON, Pa., Feb. 24 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2008.

Key events since September 30, 2008 include:

Operational:

  • Closed on acquisition of Lev Pharmaceuticals, Inc. (Lev) in October 2008;
  • Initiated commercial launch of Cinryze for routine prophylaxis of hereditary angioedema (HAE);
  • Developed and successfully launched Cinryze patient access program, CinryzeSolutions(TM);
  • Launched new sales team in December for Cinryze;
  • Achieved net Vancocin(R) sales of $50 million during fourth quarter 2008; and
  • Increased research and development expenses by 70 percent over the fourth quarter of 2007, primarily driven by maribavir and Cinryze.

Development:

  • Filed supplemental Biologics License Application (sBLA) for Cinryze for treatment of acute attacks of HAE;
  • Granted priority review by the U.S. Food and Drug Administration for Cinryze sBLA for treatment of acute attacks of HAE, with a Prescription Drug User Fee Act (PDUFA) date of June 3, 2009; and
  • Discontinued maribavir clinical development program for prophylaxis against cytomegalovirus disease in transplant patients based on the preliminary analysis of phase 3 data.

Financial Results:

  • Achieved 16th consecutive quarter of positive cash flows from operations; and
  • Ended 2008 with working capital of $305 million, which includes cash, cash equivalents and short-term investments of $276 mi
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... work by a Florida State University research team has ... your temperature, emit white light, and convert photon energy ... like a butterfly. , Biwu Ma, associate professor in ... FAMU-FSU College of Engineering, created the molecule in a ... discover that his creation has many other unique capabilities. ...
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2
... accurately while minimizing ... 6 During his annual,physical check-up in March, David Kelver,s ... the right one looked a bit swollen. The,doctor concluded, however, ... own, and sent him home. Several months later, Kelver, a ...
... showing that Microsoft SQL Server ... 1 petabyte., REDMOND, Wash., Nov. 6 ... management and business,intelligence platform, Microsoft SQL Server 2008, ... scale new heights in data warehousing,and transaction processing., ...
... at Rodman & Renshaw,10th Annual Healthcare Conference" issued on ... over PR Newswire, we are advised by a,representative of ... the first paragraph. Complete, corrected release follows:, , ... the development of microRNA-based diagnostics, announced today it,will present ...
Cached Biology Technology:Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 2Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 3Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 4Could Database Software Help Cure Alzheimer's and Save the Earth? 2Could Database Software Help Cure Alzheimer's and Save the Earth? 3/C O R R E C T I O N -- Rosetta Genomics Ltd/ 2/C O R R E C T I O N -- Rosetta Genomics Ltd/ 3/C O R R E C T I O N -- Rosetta Genomics Ltd/ 4/C O R R E C T I O N -- Rosetta Genomics Ltd/ 5/C O R R E C T I O N -- Rosetta Genomics Ltd/ 6
(Date:9/1/2014)... a life without light. They emit echolocation sounds and use ... obstacles or prey. In their brains, they have a spatial ... researchers at Technische Universitt Mnchen (TUM) has shown for the ... , Closer objects appear larger , ... the number of activated neurons in its brain increases. As ...
(Date:8/31/2014)... highly infectious bacteria C. diff , that causes ... a team at the University of Leicester. , Using ... it is possible to identify the unique ,smell, of ... diagnosis of the condition., What is more, the Leicester ... strains of the disease simply from their smell ...
(Date:8/31/2014)... in Nature Climate Change , suggests that if ... not exceed, the global targets for total greenhouse gas (GHG) ... should all think carefully about the food we choose and ... world is just one of a number of actions that ... ensure there is enough food for all. , As ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4
... clear change in salinity has been detected in the ... global rainfall and evaporation cycle., In a paper published ... the Commonwealth Scientific and Industrial Research Organisation (CSIRO) and ... of salinity in the global ocean during the past ...
... scientists has found there has been a massive reduction in ... of Antarctica.,Comparing detailed measurements taken during the Australian Antarctic program,s ... back to 1970, scientists estimate there has been as much ... Antarctic Bottom Water, the cold dense water that drives global ...
... Berlin, Germany, May 21, 2012 IMPACT World+, ... methodology was launched today in Berlin, Germany during the ... Meeting. The event featured the results of this innovative ... experts and researchers from five countries., The production and ...
Cached Biology News:Earth's water cycle intensifying with atmospheric warming 2Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3Launch of IMPACT World+ 2
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
Biology Products: